UK regulator provides update on clinical trial rules during Brexit

The UK’s medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), has released an update on clinical trials regulations following the UK’s exit from the European Union, so-called “Brexit.”

While Brexit will occur at the end of March 2019, the UK and the EU have agreed that EU rules and regulations will remain in place until the end of 2020, in order to provide continuity and a transitional period.

During this time, the EU’s new Clinical Trials Regulation (CTR), which is expected to be implemented during 2020, would apply to the UK, says the MHRA.